Rwandamuriye, 2023 - Google Patents
Biomaterial-assisted delivery of immunotherapy: a novel approach to prevent cancer recurrenceRwandamuriye, 2023
View PDF- Document ID
- 2875586414001063275
- Author
- Rwandamuriye F
- Publication year
External Links
Snippet
Biomaterial-assisted delivery of immunotherapy: a novel approach to prevent cancer recurrence
Page 1 i Biomaterial-assisted delivery of immunotherapy: a novel approach to prevent cancer
recurrence Francois Xavier Rwandamuriye Master of Infectious Diseases (UWA) This thesis is …
- 206010028980 Neoplasm 0 title abstract description 439
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases | |
| Smith et al. | Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors | |
| Han et al. | Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy | |
| Singh et al. | An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma | |
| Ali et al. | Infection-mimicking materials to program dendritic cells in situ | |
| JP2021192630A (en) | Delivery of biomolecules to immune cells | |
| Kroon et al. | Radiotherapy and cisplatin increase immunotherapy efficacy by enabling local and systemic intratumoral T-cell activity | |
| Sun et al. | The IL-1 family in tumorigenesis and antitumor immunity | |
| Atik et al. | Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells | |
| US11883424B2 (en) | Methods of making novel pharmaceutical compositions | |
| JP2016540042A (en) | Combinations of checkpoint inhibitors and therapeutics to treat cancer | |
| WO2014161887A1 (en) | Targeted cancer immune therapy | |
| CN102119214A (en) | Composition comprising in vitro expanded T-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer | |
| Yang et al. | Nanohydroxyapatite stimulates PD-L1 expression to boost melanoma combination immunotherapy | |
| Makkouk et al. | Three steps to breaking immune tolerance to lymphoma: a microparticle approach | |
| CN111182918A (en) | Methods for activating immune cells | |
| Rwandamuriye | Biomaterial-assisted delivery of immunotherapy: a novel approach to prevent cancer recurrence | |
| WO2024113006A1 (en) | Novel hydrogels | |
| US20220313724A1 (en) | Compositions for intratumoral administration and related methods | |
| Pechnikova et al. | Implantable Biomaterials for Cancer Immunotherapies | |
| RU2645464C1 (en) | Immunotherapy of breast cancer using antigen-activated dendritic cells | |
| Kim et al. | Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy | |
| Schunke | Adjuvant-loaded protein-based nanocapsules induce effective anti-cancer immunity | |
| Lucarini | Dissecting Interleukin-33/ST2-dependent pathway in antitumor immune response to melanoma | |
| Jæhger | Preclinical Evaluation of Novel Drug Delivery Platforms for the Improvement of Adoptive T cell Therapy |